These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 24384723)

  • 1. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
    Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
    Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
    Schulz R; Marchenko ND; Holembowski L; Fingerle-Rowson G; Pesic M; Zender L; Dobbelstein M; Moll UM
    J Exp Med; 2012 Feb; 209(2):275-89. PubMed ID: 22271573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells.
    Yallowitz A; Ghaleb A; Garcia L; Alexandrova EM; Marchenko N
    Cell Death Dis; 2018 May; 9(6):621. PubMed ID: 29799521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.
    Li D; Yallowitz A; Ozog L; Marchenko N
    Cell Death Dis; 2014 Apr; 5(4):e1194. PubMed ID: 24763051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis.
    Xi C; Hu Y; Buckhaults P; Moskophidis D; Mivechi NF
    J Biol Chem; 2012 Oct; 287(42):35646-35657. PubMed ID: 22847003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer.
    Klemke L; De Oliveira T; Witt D; Winkler N; Bohnenberger H; Bucala R; Conradi LC; Schulz-Heddergott R
    Cell Death Dis; 2021 Feb; 12(2):155. PubMed ID: 33542244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.
    Cheng Q; Chang JT; Geradts J; Neckers LM; Haystead T; Spector NL; Lyerly HK
    Breast Cancer Res; 2012 Apr; 14(2):R62. PubMed ID: 22510516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.
    Zhao YH; Zhou M; Liu H; Ding Y; Khong HT; Yu D; Fodstad O; Tan M
    Oncogene; 2009 Oct; 28(42):3689-701. PubMed ID: 19668225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent manner.
    Chai RC; Kouspou MM; Lang BJ; Nguyen CH; van der Kraan AG; Vieusseux JL; Lim RC; Gillespie MT; Benjamin IJ; Quinn JM; Price JT
    J Biol Chem; 2014 May; 289(19):13602-14. PubMed ID: 24692538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.
    Ganguly S; Home T; Yacoub A; Kambhampati S; Shi H; Dandawate P; Padhye S; Saluja AK; McGuirk J; Rao R
    Oncotarget; 2015 Oct; 6(31):31767-79. PubMed ID: 26397138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis.
    Meng L; Gabai VL; Sherman MY
    Oncogene; 2010 Sep; 29(37):5204-13. PubMed ID: 20622894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights from yeast into whether the inhibition of heat shock transcription factor (Hsf1) by rapamycin can prevent the Hsf1 activation that results from treatment with an Hsp90 inhibitor.
    Millson SH; Piper PW
    Oncotarget; 2014 Jul; 5(13):5054-64. PubMed ID: 24970820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bag-1-mediated HSF1 phosphorylation regulates expression of heat shock proteins in breast cancer cells.
    Kizilboga T; Özden C; Can ND; Onay Ucar E; Dinler Doganay G
    FEBS Open Bio; 2024 Sep; 14(9):1559-1569. PubMed ID: 39049197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition.
    Pastorek M; Muller P; Coates PJ; Vojtesek B
    PLoS One; 2018; 13(8):e0202758. PubMed ID: 30138434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In the yeast heat shock response, Hsf1-directed induction of Hsp90 facilitates the activation of the Slt2 (Mpk1) mitogen-activated protein kinase required for cell integrity.
    Truman AW; Millson SH; Nuttall JM; Mollapour M; Prodromou C; Piper PW
    Eukaryot Cell; 2007 Apr; 6(4):744-52. PubMed ID: 17293484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
    Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
    Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.
    Chen Y; Chen J; Yu J; Yang G; Temple E; Harbinski F; Gao H; Wilson C; Pagliarini R; Zhou W
    J Biol Chem; 2014 Jul; 289(27):18914-27. PubMed ID: 24831003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HSF1 sensitizes cancer cells to HSP90 inhibition.
    Chen Y; Chen J; Loo A; Jaeger S; Bagdasarian L; Yu J; Chung F; Korn J; Ruddy D; Guo R; McLaughlin ME; Feng F; Zhu P; Stegmeier F; Pagliarini R; Porter D; Zhou W
    Oncotarget; 2013 Jun; 4(6):816-29. PubMed ID: 23615731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.